Towards a rational treatment of essential thrombocythemia, despite limited evidence and old prejudices.

137 interleukin-5-producing T cells in idiopathic eosinophilia. New Engl J Med 1999;341:1112-20. 7. Roufosse F, Schandene L, Cogan E. Idiopathic eosinophilia. N Engl J Med 1999;342:660. 8. Bassan R, Locatelli G, Borleri G, Salvi A, Barbui T. Immunophenotypic evaluation of circulating T-cell clones in hypereosinophilic syndromes with or without abnormal CD3 and CD4 lymphocytes. Haematologica 2004;89:238-9. 9. Plötz SG, Simon HU, Darsow U, Simon D, Vassina E, Yousefi S, et al. Use of an anti-interleukin-5 antibody in the hypereosinophilic syndrome with eosinophilic dermatitis. N Engl J Med 2003:349:23349. 10. Bain BJ. An overview of translocation-related oncogenesis in the chronic myeloid leukaemias. Acta Haematol 2002;107:57-63. 11. Wilkinson K, Velloso ERP, Lopes LF, Lee C, Aster JC, Shipp MA, et al. Cloning of the t(1;5)(q23;q33) in a myeloproliferative disorder associated with eosinophilia involving of PDGFRB and response to imatinib. Blood 2003;102:4187-90. 12. Reiter A, Grand EK, Walz C, Grand FH, Schoch C, Chase A, et al. Charcaterization of two new fusion genes in the 8p11 myeloproliferative syndrome (EMS) generated by disruption of FGFR1. Blood 2002; 102:108a. 13. Invernizzi R, Benatti C, Travaglino E, Girino M, Bernasconi P, Loni C, et al. A further case of myeloproliferative syndrome with reciprocal translocation (8;13)(p11;q12). Haematologica 2004; 89:239-41. 14. Apperley J, Gardembas M, Melo J, Russell-Jones R, Bain BJ, Baxter J, et al. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the plateletderived growth factor receptor β. N Engl J Med 2002;347:481-7. 15. Cools J, De Angelo DJ, Gotlib J, Stover EH, Legare RD, Cortes J, et al. A tyrosine kinase created by the fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 2003:348:1201-14. 16. Martinelli G, Malagola M, Ottaviani E, Rosti G, Trabacchi E, Baccarani M. Imatinib mesylate can induce complete molecular remission in FIP1L1-PDGFR-α positive idiopatic hypereosinophilic syndrome. Haematologica 2004;89:236-7. 17. Pitini V, Arrigo C, Azzarello D, La Gattuta G, Amata C, Righi M, et al. Serum concentration of cardiac troponin T in patients with hypereosinophilic syndrome treated with imatinib is predictive of adverse outcome. Blood 2003;102:3456-7. 18. Tefferi A, Pardanani A. Imatinib treatment-induced cardiomyopathy in hypereosinophilic syndrome. Blood 2003; 102:3457. 19. Pardanani A, Ketterling RP, Brockman SR, Flynn HC, Paternoster SF, Shearer BM, et al. CHIC2 deletion, a surrogate marker for FIP1L1PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy. Blood 2003:102:3093-8. 20. Griffin JH, Leung J, Bruner RJ, Caligiuri MA, Briesewitz R. Discovery of a fusion kinase in EOL-1 cells and idiopathic hypereosinophilic syndrome. Proc Natl Acad Sci USA 2003; 24;100: 7830-5. 21. Klion AD, Noel P, Akin C, Law MA, Gilliland DG, Cools J, et al. Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness. Blood 2003;101:4660-6. 22. Klion AD, Robyn J, Akin C, Noel P, Brown M, Law M, et al. Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment with the myeloproliferative variant of hypereosinophilic syndrome. Blood 2004; 103:473-8 23. Pardanani A, Elliott M, Reeder T, Li C-Y, Baxter EJ, Cross NCP, et al. imatinib for systemic mastì-cell disease. Lancet 2003; 362:5357. 24. Rondoni M, Soverini S, Malagola M, Ottaviani E, Piccaluga PP, Bosi C, et al. Imatinib seems to be ineffective in patients with systemic mastocytosis carrying the Asp816Val c-KIT mutation. Blood 2003; 102:335b. 25. Bain B, Pierre R, Imbert M, Vardiman JW, Brunning RD, Flandrin G. Chronic eosinophilic leukaemia and the hypereosinophilic syndrome. In: Jaffe ES, Harris NL, Stein H and Vardiman JW, editors. World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. IARC Press: Lyon; 2001. pp. 29-31. Towards a rational treatment of essential thrombocythemia, despite limited evidence and old prejudices